The radioligand therapy was linked with a significant increase in progression-free survival and a clinically relevant increase in overall survival in patients with midgut neuroendocrine tumours
News
NICE turns down GSK’s IV Benlysta for systemic lupus
The cost watchdog said uncertain trial evidence and cost-effectiveness estimates are behind the preliminary decision
Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
What’s next for patient advocacy?
Virtual event from OVID and the Patient Partnership Index is now open for registration
‘Indian’ variant of coronavirus now dominant strain in the UK
Officials warned that early evidence suggests there may be an increased risk of hospitalisation for Delta compared to the Alpha (Kent) strain
Novartis’ CAR T therapy Kymriah shows promise in follicular lymphoma
Kymriah led to responses for the majority of treated patients, with 66% achieving a complete response (CR)
J&J’s Tremfya shows significant improvements for post-TNFi psoriatic arthritis patients
IL-23 inhibitor helped patients achieve complete skin clearance and joint symptom improvement
Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma
Combination immunotherapy treatment approved in the EU for first-line treatment of adults with unresectable MPM
NICE draft guidance does not recommend Evrysdi for SMA
NICE said it is ‘unable’ to recommend the oral treatment due to high cost-effectiveness estimates
The 2021 Sales Awards welcomes new and returning categories
The Sales Awards have introduced a brand-new category alongside a few returning classics from previous years.
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’
Updated study results showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months
FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder
Alkermes said that it is expecting to make Lybalvi available for patients in the fourth quarter of 2021
Cosentyx approved to treat plaque psoriasis in paediatric patients
IL-17A inhibitor has been cleared in the US to treat plaque psoriasis in certain patients aged six years and older
WHO authorises Sinovac’s COVID-19 vaccine for emergency use
A WHO emergency use listing (EUL) is issued when a product meets international standards for safety, efficacy and manufacturing
EC authorises Diurnal’s Efmody for CAH
First commercial launch of Efmody is expected in the third quarter of 2021
